HighTower Advisors
HALO icon

HighTower Advisors’s Halozyme HALO Stock Holding History

HighTower Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,000
Closed -$1K – 2322
2017
Q3 		$1K Buy
+1,000
New +$13.5K ﹤0.01% 2207

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors's HALO Position: Q1 2026 in Review

HighTower Advisors reduced its Halozyme (HALO) stake by 20% in Q1 2026, selling an estimated $321K and leaving 17,841 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

HighTower Advisors first reported a position in HALO in Q2 2013 and has held it in 48 quarters since. The position peaked at $5.14M in Q4 2022. 634 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • HighTower Advisors held 17,841 shares of Halozyme worth $1.15M as of Q1 2026.
  • HighTower Advisors sold 4,548 Halozyme shares in Q1 2026, an estimated $321K.
  • Halozyme made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2088 holding.
  • HighTower Advisors first reported a position in Halozyme in Q2 2013 and has held it in 48 quarters since.
  • HighTower Advisors's Halozyme position peaked at $5.14M in Q4 2022.
  • 634 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.